{"title":"玻璃体内法瑞西单抗治疗新生血管性黄斑病变的早期实际经验：FAN 研究","authors":"Constance Weber , Pascal Schipper , Isabel Stasik , Leonie Weinhold , Louisa Bulirsch , Sarah Thiele , Frank Holz , Raffael Liegl","doi":"10.1016/j.ajoint.2024.100074","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><div>This study presents real-world experiences and clinical outcomes of patients who switched to faricimab after prior treatment with other anti-vascular endothelial growth factor medication for patients with neovascular age-related macular degeneration (nAMD) in 2022.</div></div><div><h3>Design</h3><div>We evaluated all consecutive patients that received an intravitreal injection (IVI) with faricimab for nAMD and had complete follow-up visits after at least three IVI.</div></div><div><h3>Methods</h3><div>Functional and structural parameters including best-corrected visual acuity (BCVA, logMAR), foveal centre point (FCP, µm), central subfield retinal thickness (CSRT, µm) and macular volume (mm<sup>3</sup>) were evaluated after three (<em>n</em> = 71) and five (<em>n</em> = 57) faricimab injections with complete follow-up visits.</div></div><div><h3>Results</h3><div>We included 71 eyes of 63 patients. Mean BCVA at baseline was 0.49 logMAR (0 – 1.6) and did not change significantly after five faricimab injections (<em>p</em> = 0.33). Significant reductions were seen for FCP, CSRT and macular volume after the first five consecutive injections when compared to baseline (<em>p</em> < 0.0001 respectively). FCP was 388.35 µm (173–924 µm) at baseline and decreased to 279.16 µm (97 – 667) at visit 5. CSRT was 370.68 µm (202 – 1074) and decreased to 307.75 µm (168 – 590) at visit 5. Macular volume was reduced from 2.59 mm<sup>3</sup> (1.83 – 4.90) to 2.31 mm<sup>3</sup> (1.80 – 3.19) at visit 5. Intraocular inflammation was observed in one eye showing anterior chamber cells that resolved with topical corticosteroid treatment.</div></div><div><h3>Conclusions</h3><div>The results of the FAN (<strong>FA</strong>ricimab for <strong>N</strong>eovascular AMD) study indicate that faricimab improves structural outcomes in patients with recalcitrant fluid due to nAMD with no major complications observed.</div></div>","PeriodicalId":100071,"journal":{"name":"AJO International","volume":"1 4","pages":"Article 100074"},"PeriodicalIF":0.0000,"publicationDate":"2024-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Early real-world experience with intravitreal Faricimab for neovascular AMD: FAN study\",\"authors\":\"Constance Weber , Pascal Schipper , Isabel Stasik , Leonie Weinhold , Louisa Bulirsch , Sarah Thiele , Frank Holz , Raffael Liegl\",\"doi\":\"10.1016/j.ajoint.2024.100074\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Purpose</h3><div>This study presents real-world experiences and clinical outcomes of patients who switched to faricimab after prior treatment with other anti-vascular endothelial growth factor medication for patients with neovascular age-related macular degeneration (nAMD) in 2022.</div></div><div><h3>Design</h3><div>We evaluated all consecutive patients that received an intravitreal injection (IVI) with faricimab for nAMD and had complete follow-up visits after at least three IVI.</div></div><div><h3>Methods</h3><div>Functional and structural parameters including best-corrected visual acuity (BCVA, logMAR), foveal centre point (FCP, µm), central subfield retinal thickness (CSRT, µm) and macular volume (mm<sup>3</sup>) were evaluated after three (<em>n</em> = 71) and five (<em>n</em> = 57) faricimab injections with complete follow-up visits.</div></div><div><h3>Results</h3><div>We included 71 eyes of 63 patients. Mean BCVA at baseline was 0.49 logMAR (0 – 1.6) and did not change significantly after five faricimab injections (<em>p</em> = 0.33). Significant reductions were seen for FCP, CSRT and macular volume after the first five consecutive injections when compared to baseline (<em>p</em> < 0.0001 respectively). FCP was 388.35 µm (173–924 µm) at baseline and decreased to 279.16 µm (97 – 667) at visit 5. CSRT was 370.68 µm (202 – 1074) and decreased to 307.75 µm (168 – 590) at visit 5. Macular volume was reduced from 2.59 mm<sup>3</sup> (1.83 – 4.90) to 2.31 mm<sup>3</sup> (1.80 – 3.19) at visit 5. Intraocular inflammation was observed in one eye showing anterior chamber cells that resolved with topical corticosteroid treatment.</div></div><div><h3>Conclusions</h3><div>The results of the FAN (<strong>FA</strong>ricimab for <strong>N</strong>eovascular AMD) study indicate that faricimab improves structural outcomes in patients with recalcitrant fluid due to nAMD with no major complications observed.</div></div>\",\"PeriodicalId\":100071,\"journal\":{\"name\":\"AJO International\",\"volume\":\"1 4\",\"pages\":\"Article 100074\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-10-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"AJO International\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2950253524000741\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"AJO International","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2950253524000741","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Early real-world experience with intravitreal Faricimab for neovascular AMD: FAN study
Purpose
This study presents real-world experiences and clinical outcomes of patients who switched to faricimab after prior treatment with other anti-vascular endothelial growth factor medication for patients with neovascular age-related macular degeneration (nAMD) in 2022.
Design
We evaluated all consecutive patients that received an intravitreal injection (IVI) with faricimab for nAMD and had complete follow-up visits after at least three IVI.
Methods
Functional and structural parameters including best-corrected visual acuity (BCVA, logMAR), foveal centre point (FCP, µm), central subfield retinal thickness (CSRT, µm) and macular volume (mm3) were evaluated after three (n = 71) and five (n = 57) faricimab injections with complete follow-up visits.
Results
We included 71 eyes of 63 patients. Mean BCVA at baseline was 0.49 logMAR (0 – 1.6) and did not change significantly after five faricimab injections (p = 0.33). Significant reductions were seen for FCP, CSRT and macular volume after the first five consecutive injections when compared to baseline (p < 0.0001 respectively). FCP was 388.35 µm (173–924 µm) at baseline and decreased to 279.16 µm (97 – 667) at visit 5. CSRT was 370.68 µm (202 – 1074) and decreased to 307.75 µm (168 – 590) at visit 5. Macular volume was reduced from 2.59 mm3 (1.83 – 4.90) to 2.31 mm3 (1.80 – 3.19) at visit 5. Intraocular inflammation was observed in one eye showing anterior chamber cells that resolved with topical corticosteroid treatment.
Conclusions
The results of the FAN (FAricimab for Neovascular AMD) study indicate that faricimab improves structural outcomes in patients with recalcitrant fluid due to nAMD with no major complications observed.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
